CAI logo

CAI
Caris Life Sciences Inc.

875
Mkt Cap
$5.2B
Volume
8.27M
52W High
$42.50
52W Low
$17.15
PE Ratio
-9.61
CAI Fundamentals
Price
$18.41
Prev Close
$18.81
Open
$18.80
50D MA
$21.91
Beta
0.38
Avg. Volume
2.42M
EPS (Annual)
-$1.90
P/B
9.01
Rev/Employee
$439,887.87
$7,250.15
Loading...
Loading...
News
all
press releases
Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients
Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients Caris Life Sciences Announces Another Breakthrough Study for GPSai in...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer
Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early...
PR Newswire·6d ago
News Placeholder
Canaccord Genuity Group Cuts Caris Life Sciences (NASDAQ:CAI) Price Target to $22.00
Canaccord Genuity Group lowered their price target on Caris Life Sciences from $30.00 to $22.00 and set a "hold" rating on the stock in a research report on Friday...
MarketBeat·9d ago
News Placeholder
Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting
Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting PR Newswire IRVING, Texas, March 11, 2026...
PR Newswire·11d ago
News Placeholder
Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer
Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer Caris Life Sciences Launches a Novel Caris AI...
PR Newswire·13d ago
News Placeholder
Wall Street Zen Upgrades Caris Life Sciences (NASDAQ:CAI) to Buy
Wall Street Zen upgraded Caris Life Sciences from a "hold" rating to a "buy" rating in a research report on Saturday...
MarketBeat·15d ago
News Placeholder
BTSG vs. CAI: Which Stock Is the Better Value Option?
BTSG vs. CAI: Which Stock Is the Better Value Option?
Zacks·19d ago
News Placeholder
Caris Life Sciences (NASDAQ:CAI) Shares Gap Up Following Better-Than-Expected Earnings
Caris Life Sciences (NASDAQ:CAI) Shares Gap Up After Better-Than-Expected Earnings...
MarketBeat·23d ago
News Placeholder
Caris Life Sciences Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
read more...
Benzinga·23d ago
News Placeholder
Cancer Test Maker Caris Life Sciences Unveils Breakthrough In Early Cancer Detection, Profit Surprise
Caris Life Sciences stock jumps after earnings crush estimates, sales soar 125%, and cancer test data show strong early results.read more...
Benzinga·23d ago
<
1
2
...
>

Latest CAI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.